Letter to the Editor
The authors highlight many excellent points regarding the well-established safety of rifaximin. They identify a study by Tandon et al 1 that evaluated the frequency of antibiotic-resistant bacterial infections in patients with cirrhosis and concluded that rifaximin exposure within 30 days was not associated with an increase in antibiotic-resistant bacterial infections. We should point out that that study was conducted from July 2009 to November 2010 and that out of a total of 70 culture-positive patients, only 16 were on rifaximin. 1 Antibiotic resistance for Staphylococcus was defined by methicillin or vancomycin resistance. In the culture-positive patients, 10 grew Staphylococcus aureus, with no mention of which of them was exposed to rifaximin and whether rifampin resistance was tested. 1 We cannot draw any meaningful conclusions regarding rifampin resistance from this study. Tandon et al 1 additionally make the claim that the development of resistance is time dependent and that future studies are needed to reassess the effect of long-term exposure of rifaximin on resistance. The authors also point to the TARGET 3 trial, which evaluated diarrhea-predominant irritable bowel syndrome for short courses of rifaximin (2 weeks) and concluded that rifaximin exposure did not lead to clinically significant or persistent rifampin resistance. 2 However, during the second phase of the study (the double-blind phase), isolates exposed to rifaximin showed an increase in rifampin-resistant staphylococci, from 3.1% (2/65) at baseline to 17.2% (11/64) after 2 weeks, a 5-fold increase. 2 In the placebo group, rifampin resistance rates were 2.1% (1/48) at baseline and 3.2% (2/63) after 2 weeks.
2 Furthermore, 61.1% (11/18) of patients on rifaximin had rifampin-resistant staphylococci detected in the perianal area after 2 weeks of treatment compared with 16.7% (2/12) of patients on placebo. It should be pointed out that both rifampin and rifaximin resistance rates weaned with time, allowing the authors to make the conclusion that no persistent resistance was observed. This disappearance of resistance has been previously reported. 3 However, we have no knowledge as to what would happen to the resistance profiles of the organisms in these patients if rifampin were later introduced. Would rifampin resistance reemerge quicker?
In our report, we attempt to highlight that rifaximin-associated rifampin resistance is possible. 4 We do not make any claims regarding an increase in the frequency of infections with rifaximin. We propose potential mechanisms as to how this resistance is occurring. Small-intestine bacterial overgrowth and hepatic failure are 2 conditions that result in increased absorption of rifaximin. 4 Low-level absorption is particularly concerning because subinhibitory concentrations are more closely associated with the development of resistance. 5 Even without absorption, disruption of gut flora and colonization of the perianal area is possible and can occur in as little as 2 weeks. 2 Our intentions for reporting our findings were not to imply that rifaximin leads to increased rates of infections caused by resistant organisms, but to point out that rifampin resistance warrants further exploration, including active surveillance studies in patients on chronic rifaximin. 4 The necessity of rifampin in treating prostheticdevice infections and tuberculosis makes any potential threat, even if rare, worthy of further investigation. 
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